Two teams from JOLIOT (SPI / SCBM), in collaboration with the University of Cincinnati, confirm the interest of a drug candidate to treat the congenital creatine deficiency syndrome, a rare neurological childhood disease, responsible for developmental delays and intellectual disability. The results obtained in an animal model of the disease show that it is possible to administer, nasally, dodecyl creatine ester-loaded microspheres, thus improving the cognitive functions of treated animals.